Race Oncology's (ASX:RAC) bisantrene shows promise in treating multiple myeloma

Race Oncology reported preclinical findings on its lead compound, bisantrene, demonstrating its efficacy in treating multiple myeloma when used alone and in combination with the proteasome inhibitor carfilzomib.

The preclinical studies showed that bisantrene effectively killed human multiple myeloma cells at clinically relevant concentrations in cell culture and mouse models.

When combined with carfilzomib, the treatment slowed disease progression more significantly than bisantrene alone.

"The potential for using bisantrene to not only better treat multiple myeloma but also protect patients from the heart damage caused by carfilzomib is worthy of further investigation," said Daniel Tillett, CEO of Race Oncology.

Race Oncology plans to advance further preclinical studies to understand the mechanisms behind the observed therapeutic effects and cardioprotection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":316250083684392,"tweetId":"316250083684392","gmtCreate":1718239202169,"gmtModify":1718242656154,"author":{"id":4169784042383112,"authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":118,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/50a37e2f12843ce417de4a89a869f74b"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/50a37e2f12843ce417de4a89a869f74b"}],"title":"Race Oncology's (ASX:RAC) bisantrene shows promise in treating multiple myeloma","html":"<html><head></head><body><img src=\"https://community-static.tradeup.com/news/50a37e2f12843ce417de4a89a869f74b\">\nFull story: <a href=\"https://grafa.com/news/race-oncology-s--asx-rac--bisantrene-shows-promise-in-treating-multiple-myeloma-235065?utm_source=ttmfinancial&amp;medium=social&amp;campaign=235065&amp;referralcode=A314DFDBE96C354756A893C6E3E02493\">https://grafa.com/news/race-oncology-s--asx-rac--bisantrene-shows-promise-in-treating-multiple-myeloma-235065</a>\nRace Oncology reported preclinical findings on its lead compound, bisantrene, demonstrating its efficacy in treating multiple myeloma when used alone and in combination with the proteasome inhibitor carfilzomib. \nThe preclinical studies showed that bisantrene effectively killed human multiple myeloma cells at clinically relevant concentrations in cell culture and mouse models. \nWhen combined with carfilzomib, the treatment slowed disease progression more significantly than bisantrene alone. \n\"The potential for using bisantrene to not only better treat multiple myeloma but also protect patients from the heart damage caused by carfilzomib is worthy of further investigation,\" said Daniel Tillett, CEO of Race Oncology. \nRace Oncology plans to advance further preclinical studies to understand the mechanisms behind the observed therapeutic effects and cardioprotection.</body></html>","htmlText":"<html><head></head><body><img src=\"https://community-static.tradeup.com/news/50a37e2f12843ce417de4a89a869f74b\">\nFull story: <a href=\"https://grafa.com/news/race-oncology-s--asx-rac--bisantrene-shows-promise-in-treating-multiple-myeloma-235065?utm_source=ttmfinancial&amp;medium=social&amp;campaign=235065&amp;referralcode=A314DFDBE96C354756A893C6E3E02493\">https://grafa.com/news/race-oncology-s--asx-rac--bisantrene-shows-promise-in-treating-multiple-myeloma-235065</a>\nRace Oncology reported preclinical findings on its lead compound, bisantrene, demonstrating its efficacy in treating multiple myeloma when used alone and in combination with the proteasome inhibitor carfilzomib. \nThe preclinical studies showed that bisantrene effectively killed human multiple myeloma cells at clinically relevant concentrations in cell culture and mouse models. \nWhen combined with carfilzomib, the treatment slowed disease progression more significantly than bisantrene alone. \n\"The potential for using bisantrene to not only better treat multiple myeloma but also protect patients from the heart damage caused by carfilzomib is worthy of further investigation,\" said Daniel Tillett, CEO of Race Oncology. \nRace Oncology plans to advance further preclinical studies to understand the mechanisms behind the observed therapeutic effects and cardioprotection.</body></html>","text":"Full story: https://grafa.com/news/race-oncology-s--asx-rac--bisantrene-shows-promise-in-treating-multiple-myeloma-235065 Race Oncology reported preclinical findings on its lead compound, bisantrene, demonstrating its efficacy in treating multiple myeloma when used alone and in combination with the proteasome inhibitor carfilzomib. The preclinical studies showed that bisantrene effectively killed human multiple myeloma cells at clinically relevant concentrations in cell culture and mouse models. When combined with carfilzomib, the treatment slowed disease progression more significantly than bisantrene alone. \"The potential for using bisantrene to not only better treat multiple myeloma but also protect patients from the heart damage caused by carfilzomib is worthy of further investigation,\" said Daniel Tillett, CEO of Race Oncology. Race Oncology plans to advance further preclinical studies to understand the mechanisms behind the observed therapeutic effects and cardioprotection.","highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/316250083684392","repostId":0,"isVote":1,"tweetType":1,"viewCount":43,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["RAC.AU"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":873,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/316250083684392"}